Regeneron Pharmaceuticals, Inc.
STABLE ANTIBODY FORMULATION

Last updated:

Abstract:

The present disclosure provides stable pharmaceutical formulations comprising a human antibody that specifically binds to Ebola Virus (EBOV). In certain embodiments, the formulations contain, in addition to an anti-EBOV antibody, a buffer, an amino acid, a non-ionic surfactant, and a stabilizer. The pharmaceutical formulations of the present disclosure exhibit a substantial degree of antibody stability upon stress, for example, agitation during transport, and storage, for example, storage at temperatures greater than 40.degree. C.

Status:
Application
Type:

Utility

Filling date:

22 Jan 2021

Issue date:

19 Aug 2021